Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.59 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.32 |
| ▸ | CHRNG | P07510 | 2/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.32 |
| ▸ | CHRND | Q07001 | 2/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 9/20 | 0.31 |
| ▸ | MMP3 | P08254 | 5/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.30 |
| ▸ | CPB1 | P15086 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22309062 | 0.91 | TUBB1 (0.57) | TUBB1MMP2MMP3MMP1MMP9 | |
| SCHEMBL20732182 | 0.91 | TUBB1 (0.57) | TUBB1MMP2MMP3MMP1MMP9 | |
| SCHEMBL6801949 | 0.88 | TUBB1 (0.62) | TUBB1MMP2MMP3MMP1MMP9 | |
| SCHEMBL6802822 | 0.87 | TUBB1 (0.61) | TUBB1MMP1ADAM17 | |
| SCHEMBL6802182 | 0.87 | TUBB1 (0.64) | TUBB1MMP2MMP3MMP1ADAM17 | |
| SCHEMBL58638 | 0.86 | TUBB1 (0.63) | TUBB1MMP2MMP3ADAM17 | |
| SCHEMBL4369885 | 0.85 | TUBB1 (0.67) | TUBB1MMP2MMP3MMP1MMP9 | |
| SCHEMBL4369892 | 0.85 | TUBB1 (0.67) | TUBB1MMP2MMP3MMP1MMP9 | |
| SCHEMBL57908 | 0.85 | TUBB1 (0.69) | TUBB1MMP2MMP3MMP1MMP9 | |
| SCHEMBL6675641 | 0.85 | TUBB1 (0.69) | TUBB1MMP2MMP3MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | POU5F1, POU2F1, POU2F2 | TUBB1 119/4885CHRNA1 682/4885CHRNG 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.